Randomized trial · people
Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a head-to-head trial, efinopegdutide cut liver fat more than semaglutide at these doses, with similar weight loss and somewhat more gut side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 145
- Published
- 2023
- Journal
- J Hepatol
What they tested
The team tested whether efinopegdutide, which acts on both GLP-1 and glucagon receptors, lowers liver fat more than semaglutide in people with non-alcoholic fatty liver disease (NAFLD).
How the study was done
A phase IIa randomized, open-label trial (everyone knew which drug they got) in 145 people with NAFLD and at least 10% liver fat, 33.1% of whom had type 2 diabetes. They were assigned to efinopegdutide 10 mg or semaglutide 1 mg, each given under the skin once a week for 24 weeks, with liver fat measured by MRI.

Model. Individual results vary.
What they found
At week 24, liver fat fell by an average of 72.7% from its starting level in the efinopegdutide arm (90% CI 66.8-78.7) and by 42.3% in the semaglutide arm (90% CI 36.5-48.1), a significant gap (p <0.001). Body weight dropped 8.5% with efinopegdutide and 7.1% with semaglutide, a gap that was not statistically significant (p = 0.085). Side effects were slightly more common with efinopegdutide, mostly stomach and gut problems.
What it doesn’t show
The trial was open-label, ran only 24 weeks and compared one dose of each drug. It measured liver fat on MRI, not liver inflammation or scarring, so it does not show an effect on NASH itself.
The paper
Romero-Gómez et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023.
The compound
More studies on Efinopegdutide
- Efinopegdutide: MASH resolved in up to 63% vs 13% on placeboRandomized trial · people · 2026
- Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeksRandomized trial · people · 2021
- Every study on Efinopegdutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.